Xeris Pharmaceuticals | XERS - Sales Revenues


Xeris Pharmaceuticals reported $83.13M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Celltrion KRW 1.24T 90B Jun/2026
Cspc Pharmaceutical CNY 6.47B 355.1M Mar/2026
Deva Holding AS TRY 2.32B 418.58M Sep/2023
Dianthus Therapeutics USD 463K 179K Mar/2026
Divis Laboratories Ltd INR 27.58B 730M Jun/2026
Eli Lilly USD 22.97B 3.17B Jun/2026
Kangmei Pharma CNY 1.08B 288.27M Mar/2026
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
Laboratorios Farma EUR 448.66M 67.82M Dec/2023
Medical Developments International AUD 21.57M 12.04M Dec/2025
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neuren Pharmaceuticals AUD 42.24M 28.1M Dec/2025
Organigram Holdings CAD 59.79M 3.74M Mar/2026
Pacira USD 192.4M 15.4M Jun/2026
Perrigo USD 1.02B 51M Jun/2026
Pharma Mar EUR 50M 7.1M Jun/2026
Qiagen NV USD 463.12M 43.9M Jun/2026
Sartorius EUR 911.8M 12.7M Jun/2026
Sino Biopharmaceutical CNY 14.26B 3.31B Dec/2025
Supernus Pharmaceuticals USD 219.1M 11.39M Jun/2026
Tilray USD 217.51M 74.75M Dec/2025
Zealand Pharma A/S 34M 34.92M Mar/2026
Zhangzhou Pientzehuang Pharmaceutical CNY 2.72B 837.63M Mar/2026